Abstract Details

Title Spinal Cord Lesions and Disability in Hispanics with Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) P04 - (-)

Poster/Presentation
Number 129

Objective

Background BACKGROUND: The extent of spinal cord pathology and clinical characteristics in Hispanics with MS is unknown.

Design/Methods DESIGN/METHODS: Cross-sectional study from University of Southern California's Hispanic MS Registry. OSMS was defined as relapses predominantly confined to spinal cord and optic nerve >5 years disease duration in patients who do not meet diagnostic criteria for neuromyelitis optica. Comparisons were made between cases with longitudinally extensive (LESCLs), scattered (sSCLs) and no spinal cord lesions (noSCLs). Logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CIs) associated with disability (expanded disability status scale >=4.0; EDSS).

Results RESULTS: A total of 164 cases with relapsing-remitting MS and brain and spinal cord 1.5 Tesla MRIs were included. Most were female ([sim]58%) and of Mexican background (78%). Of the cases with spinal cord lesions (n=125), 25% (n=31) had LESCLs. Cases with LESCLs were more likely to have higher disability scores (EDSS mean=4.95 ±SD 1.77 vs. 3.0 ± 2.25, p= 0.03) and follow an OSMS course (32% vs. 3%, p=0.04) when compared with sSCLs. Cases with LESCLs were also more likely to have more disability and longer disease duration (average 12.8 vs. 4.9 years, p=0.001) compared with noSCLs (mean EDSS=2.06 ± 1.85, p=0.0001). Presence of LESCLs was associated with more disability even after adjusting for age, gender and disease duration (OR=7.7, 95%CI=1.79-32.88; p=0.01) while sSCLs were not (OR=2.6, 95%CI=0.86-8.08 p=0.91) compared with noSCLs.

Conclusions CONCLUSIONS: : In this pilot study we found that most Hispanics with MS had some degree of spinal cord involvement. In addition, LESCLs were a predictor of disability in Hispanics compared to noSCLs. These findings suggest that LESCLs may be an early marker of poor prognosis in MS warranting further study.

Authors/Disclosures
Lilyana M. Amezcua, MD, FAAN (USC) PRESENTER	Dr. Amezcua has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD serono. Dr. Amezcua has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Amezcua has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Amezcua has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for genentech. The institution of Dr. Amezcua has received research support from National MS Society. The institution of Dr. Amezcua has received research support from Genentech. The institution of Dr. Amezcua has received research support from Bristol Myers Squibb Foundation. The institution of Dr. Amezcua has received research support from NIH NINDS. The institution of Dr. Amezcua has received research support from Sanofi/Genzyme. The institution of Dr. Amezcua has received research support from Alexion.
Alexander Lerner	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
John Q. Trojanowski, MD, PhD (University of PA School of Med)	Dr. Trojanowski has nothing to disclose.
Leslie P. Weiner, MD	No disclosure on file
Annette M. Langer-Gould, MD, PhD (Kaiser Permanente Southern California)	An immediate family member of Dr. Langer-Gould has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of American Thoracic Society. The institution of Dr. Langer-Gould has received research support from PCORI. The institution of an immediate family member of Dr. Langer-Gould has received research support from PCORI, ARQ, NIH. Dr. Langer-Gould has a non-compensated relationship as a Voting Member with ICER CTAF Panel that is relevant to AAN interests or activities.

��ɫ��

��ɫ��